Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Feb;34(2):135-139.
doi: 10.13201/j.issn.1001-1781.2020.02.009.

[Effect of sublingual immunotherapy with Dermatophagoides Farinae on the expression of specific IgG4 in patients with allergic rhinitis in Hainan area]

[Article in Chinese]
Qiuju Huang  1 , Xin Wei  1 , Xia Lin  1 , Jing Zheng  1 , Haiyan Huang  1
Affiliations
Randomized Controlled Trial

[Effect of sublingual immunotherapy with Dermatophagoides Farinae on the expression of specific IgG4 in patients with allergic rhinitis in Hainan area]

[Article in Chinese]
Qiuju Huang et al. Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2020 Feb.

Abstract
in English, Chinese

Objective:The aim of this study is to investigate the effect of sublingual immunotherapy with Dermatophagoides Farinae on the expression of specific IgG4（sIgG4） in patients with allergic rhinitis （AR） in Hainan area. Method:Seventy-two patients with dust-mite allergic rhinitis, all three generations of whom were local islanders in Hainan, were randomly divided into control group（36 cases） and SLIT group（36 cases）. sIgG4 and sIgE expression levels were detected before treatment, 6 months after treatment, 12 months after treatment, and 18 months after treatment. The patient's symptom score, medication score, VAS score and adverse reactions was also assessed. Finally, through statistical analysis of the relevant data collected at 4 time points in the two groups of patients, the efficacy, safety and changes of sIgG4 antibody expression level in patients with allergic rhinitis receiving sublingual specific immunotherapy in Hainan were observed. Result:Symptoms scores, medication scores and VAS scores were significantly improved in the SLIT group after treatment compared with before treatment（P<0.05）, and serum sIgG4 increased significantly（P<0.01）, serum sIgE showed no significant change（P>0.05）. In the control group, symptom scores, medication scores and VAS scores were also significantly improved compared with before treatment（P<0.05）, while serum sIgG4 and sIgE showed no significant change（P>0.05）. When comparing the two groups, Symptoms scores, medication scores and VAS scores of the SLIT group were significantly lower than those of the control group at 12 months and 18 months after treatment（P<0.05）. sIgG4 expression levels in the SLIT group were significantly higher than those in the control group after 6, 12 and 18 months of treatment（P<0.01）. There was no significant difference in sIgE expression level between the two groups（P>0.05）. No severe systemic adverse reactions occurred in the two groups, and 3 patients showed mild adverse reactions in the SLIT group. Conclusion:Sublingual immunotherapy of Dermatophagoides Farinae was effective and could increase the expression of sIgG4 in patients with Dermatophagoides farinae AR, sIgG4 is expected to be an immunological marker for the objective evaluation of the clinical efficacy of Hapten.

目的：探讨粉尘螨舌下免疫治疗对于海南地区变应性鼻炎（AR）患者的特异性IgG4（sIgG4）表达水平的影响。 方法：选取72例三代均为海南本地岛民且诊断为粉尘螨变应性鼻炎的患者，随机分为对照组36例和SLIT组36例，分别在治疗前、治疗6个月、治疗12个月、治疗18个月后检测患者sIgG4、sIgE的表达水平，评估患者的症状评分、用药评分及VAS评分，同时记录不良反应。最终通过对2组患者4个时间点收集到的相关数据进行统计分析，观察海南地区AR患者接受舌下特异性免疫治疗后其sIgG4抗体表达水平的改变情况。 结果：与治疗前相比，治疗后SLIT组患者的症状评分、药物评分及VAS评分均显著改善（P<0.05），血清sIgG4显著升高（P<0.01），血清sIgE无显著性变化（P>0.05）；对照组患者的症状评分、药物评分和VAS评分也有显著改善（P<0.05），血清sIgG4、血清sIgE水平无显著性变化（P>0.05）。2组相比，SLIT组在治疗12个月和18个月后症状评分、用药评分及VAS评分均显著低于对照组（P<0.05）；SLIT组sIgG4表达水平在治疗6个月、12个月和18个月后均显著高于对照组（P<0.01）。2组sIgE表达水平无明显差异（P>0.05）。2组均未出现严重不良反应，SLIT组出现2例轻微不良反应。 结论：粉尘螨舌下免疫治疗疗效显著，同时可显著增加粉尘螨AR患者体内sIgG4的表达水平，sIgG4有望作为客观评估变应原特异性免疫治疗临床疗效的一个免疫学指标。.

Keywords: allergic rhinitis; sIgG4; sublingual specific immunotherapy.

PubMed Disclaimer

Conflict of interest statement

The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.

Similar articles

See all similar articles

Cited by

References

    1. Wang XD, Zheng M, Lou HF, et al. An increased prevalence of self-reported allergic rhinitis in major Chinese cities from 2005 to 2011. Allergy. 2016;71(8):1170–1180. doi: 10.1111/all.12874. - DOI - PMC - PubMed
    1. Zhang Y, Zhang L. Prevalence of allergic rhinitis in China. Allergy Asthma Immunol Res. 2014;6(2):105–113. doi: 10.4168/aair.2014.6.2.105. - DOI - PMC - PubMed
    1. Kakli HA, Riley TD. Allergic rhinitis. Prim Care. 2016;43(3):465–475. doi: 10.1016/j.pop.2016.04.009. - DOI - PubMed
    1. Surda P, Fokkens WJ. Novel, Alternative, and Controversial Therapies of Rhinitis. Immunol Allergy Clin North Am. 2016;36(2):401–423. doi: 10.1016/j.iac.2015.12.014. - DOI - PubMed
    1. Hanci D, Şahin E, Muluk NB, et al. Immunotherapy in all aspects. Eur Arch Otorhinolaryngol. 2016;273(6):1347–55. doi: 10.1007/s00405-015-3553-5. - DOI - PubMed

Publication types

Substances

LinkOut - more resources